- Home
- DTSQ vs DBVT Comparison
DTSQ vs DBVT Comparison
Compare DTSQ & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTSQ
- DBVT
- Stock Information
- Founded
- DTSQ 2022
- DBVT 2002
- Country
- DTSQ United States
- DBVT France
- Employees
- DTSQ N/A
- DBVT N/A
- Industry
- DTSQ
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DTSQ
- DBVT Health Care
- Exchange
- DTSQ NYSE
- DBVT Nasdaq
- Market Cap
- DTSQ 91.6M
- DBVT 102.0M
- IPO Year
- DTSQ 2024
- DBVT N/A
- Fundamental
- Price
- DTSQ $10.32
- DBVT $9.83
- Analyst Decision
- DTSQ
- DBVT Strong Buy
- Analyst Count
- DTSQ 0
- DBVT 3
- Target Price
- DTSQ N/A
- DBVT $13.67
- AVG Volume (30 Days)
- DTSQ 803.0
- DBVT 83.8K
- Earning Date
- DTSQ 01-01-0001
- DBVT 04-30-2025
- Dividend Yield
- DTSQ N/A
- DBVT N/A
- EPS Growth
- DTSQ N/A
- DBVT N/A
- EPS
- DTSQ 0.25
- DBVT N/A
- Revenue
- DTSQ N/A
- DBVT $3,497,000.00
- Revenue This Year
- DTSQ N/A
- DBVT $1,700.53
- Revenue Next Year
- DTSQ N/A
- DBVT $535.67
- P/E Ratio
- DTSQ $40.59
- DBVT N/A
- Revenue Growth
- DTSQ N/A
- DBVT N/A
- 52 Week Low
- DTSQ $9.96
- DBVT $0.44
- 52 Week High
- DTSQ $10.37
- DBVT $9.90
- Technical
- Relative Strength Index (RSI)
- DTSQ N/A
- DBVT 68.26
- Support Level
- DTSQ N/A
- DBVT $9.18
- Resistance Level
- DTSQ N/A
- DBVT $10.12
- Average True Range (ATR)
- DTSQ 0.00
- DBVT 0.74
- MACD
- DTSQ 0.00
- DBVT -0.01
- Stochastic Oscillator
- DTSQ 0.00
- DBVT 84.32
About DTSQ DT CLOUD STAR ACQUISITION CORP
DT Cloud Star Acquisition Corp is a blank check company.
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.